The Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxImmunotherapy (potential) Breakthrough: Turning Cold Tumors Hot, Prostate Cancer is the Perfect Candidate
/0 Comments/in Immunotherapy, Preclinical Research/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxOnchilles Pharma’s (potentially) Groundbreaking Pan-Cancer Therapeutics: Targeting the ELANE Pathway
/0 Comments/in Immunotherapy, Preclinical Research/by MaxTags
abiraterone acetate ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide diet docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial survival outcomes T-cell therapy theranostics treatment resistance
Latest Posts
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
- Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025